The Max Foundation Delivers First Treatment into Mozambique

The Max Foundation Delivers First Treatment into Mozambique

On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

“The Max Access Solutions provides hope in the form of innovative cancer treatment in neglected regions of the world,” says Pat Garcia-Gonzalez, CEO of The Max Foundation. “Today we reached a new frontier and I am deeply grateful to all who made it possible.”

In the beginning of 2018, Cathy Scheepers, The Max Foundation’s Region Head of Africa & Middle East visited the hospital in Maputo and learned of over 100 chronic myeloid leukemia (CML) patients who were unable to access treatment. The only way patients could access treatment was to travel to South Africa, a challenging day of travel. Mozambique is one of the poorest countries in the world, and for the majority of people living there, traveling to find treatment was simply not an option.

“Over 100 patients who have had a five-year life expectancy now have access to live normal lives.” says Cathy. “We’re changing not only the physician and patient perspectives, but also the broader community perspective that cancer is not always a death sentence. There is hope if you have access to treatment.”

Thank you to all who made access to treatment in Mozambique a reality: the passionate donors, physicians in Maputo, Humanitarian PACT partner Novartis, advisors, and The Max Foundation’s global team members. Everyone involved worked tirelessly to expand the scope of Max Access Solutions into the hands of those awaiting treatment, and now, patients have the chance to spend more days with their families, communities, and loved ones.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Join us November 6th for the International CML Foundation Forum at AORTIC

    Join us November 6th for the International CML Foundation Forum at AORTIC

    The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world. During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML. When: Wednesday,….

  • The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    The Max Foundation Establishes Unprecedented Network of Leading Cancer Providers in LMIC

    In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.

  • The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….